Human DevelopmentHCANCT06497673
Sanger Human Cell Atlasing Project
An observational study of Human Development and Genetic Disease, run by The Wellcome Sanger Institute at 1 site in United Kingdom.
Trial summary
"Cell Atlasing" refers to a novel strategy to characterise cells in tissues at the molecular level in a quantitative manner. The international Human Cell Atlas consortium brings together a community of biologists, clinicians, technologists, physicists, computational scientists, software engineers, and mathematicians… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Human Development, Genetic Disease
- What is being tested?
- sample collection
- How many people
- 4,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 16 Dec 2019to 7 Nov 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals, to facilitate atlasing of the entire human body. Samples for this study will be obtained from tissue banks and ethically approved research studies where consent has been taken for use of the samples in future research. Prospective samples will also be collected via collaborators at NHS sites. This will allow for the collection of all cell types to fulfil the aims of the study. We will provide collaborators with study specific participant information sheets and informed consent forms to recruit potential donors.
Who may be able to join
- Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals.
- All samples will have fully informed consent for use in research.
Who cannot join
- Samples taken without consent for use in future research
- Samples taken from individuals without the capacity to consent to use in research
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Sanger Human Cell Atlasing Project. Defining Human Cells in Terms of Gene Expression, Physiological States,Developmental Trajectories, and Location.
"Cell Atlasing" refers to a novel strategy to characterise cells in tissues at the molecular level in a quantitative manner. The international Human Cell Atlas consortium brings together a community of biologists, clinicians, technologists, physicists, computational scientists, software engineers, and mathematicians to capitalise on drawing together leaders with various biological, technical and computational expertise. The project is based on the aim to define all human cell types in terms of their distinctive patterns of gene expression, physiological states, developmental trajectories, and location. This will pave the way to create a reference map of all human cells as a basis for understanding human health and diagnosing, monitoring, and treating disease.
Read the detailed description
Previous methods for quantifying molecular states of cells included microarray and standard RNA-seq analysis on a tissue section (RNA-seq is a technique to look at the activity of all the genes in a cell). These methods estimate the activity of any given gene by averaging the signal from millions of cells. Given the heterogeneity of cell populations (i.e.how uniform they are), measurement of the mean values of signals overlooks the internal interactions and differences within a cell population that may be crucial for maintaining normal tissue function and facilitating disease progression.
The Sanger Human Cell Atlasing project will adopt various genomic approaches that will provide genome-wide information in a single experiment. This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches. Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.
- Conditions
- Human Development, Genetic Disease
- Being tested
- sample collection
- Medical subject headings
- Genetic Diseases, Inborn
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sample collectionOther
New collected samples, as well as surplus surgical and diagnostic samples.
What is being measured
The primary outcome is the main question the study is designed to answer.
This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches.
Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2024
- Study start16 Dec 2019
- Primary completion7 Nov 2029 (estimated)
- Study completion7 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human DevelopmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Wellcome Sanger Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sarah Teichmann, Principal investigator, Wellcome Sanger Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06497673
- Sponsor's protocol ID
- 260474
- Acronym
- HCA
- Status last verified
- Jul 2024
- First submitted
- 4 Jul 2024
- Last updated
- 12 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sanger Human Cell Atlasing Project. Defining Human Cells in Terms of Gene Expression, Physiological States,Developmental Trajectories, and Location.
- ClinicalTrials.gov ID
- NCT06497673
- Acronym / sponsor ID
- HCA / 260474
- Conditions
- Human Development, Genetic Disease
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- The Wellcome Sanger InstituteUniversity, hospital or other
- Study start
- 16 Dec 2019 (actual)
- Primary completion
- 7 Nov 2029 (estimated)
- Study completion
- 7 Nov 2029 (estimated)
- First posted
- 12 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
"Cell Atlasing" refers to a novel strategy to characterise cells in tissues at the molecular level in a quantitative manner. The international Human Cell Atlas consortium brings together a community of biologists, clinicians, technologists, physicists, computational scientists, software engineers, and mathematicians to capitalise on drawing together leaders with various biological, technical and computational expertise. The project is based on the aim to define all human cell types in terms of their distinctive patterns of gene expression, physiological states, developmental trajectories, and location. This will pave the way to create a reference map of all human cells as a basis for understanding human health and diagnosing, monitoring, and treating disease.
Detailed description
Previous methods for quantifying molecular states of cells included microarray and standard RNA-seq analysis on a tissue section (RNA-seq is a technique to look at the activity of all the genes in a cell). These methods estimate the activity of any given gene by averaging the signal from millions of cells. Given the heterogeneity of cell populations (i.e.how uniform they are), measurement of the mean values of signals overlooks the internal interactions and differences within a cell population that may be crucial for maintaining normal tissue function and facilitating disease progression.
The Sanger Human Cell Atlasing project will adopt various genomic approaches that will provide genome-wide information in a single experiment. This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches. Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.
Study design
- Observational model
- Other
- Time perspective
- Other
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals, to facilitate atlasing of the entire human body. Samples for this study will be obtained from tissue banks and ethically approved research studies where consent has been taken for use of the samples in future research. Prospective samples will also be collected via collaborators at NHS sites. This will allow for the collection of all cell types to fulfil the aims of the study. We will provide collaborators with study specific participant information sheets and informed consent forms to recruit potential donors.
Key inclusion criteria (2 listed)
- Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals.
- All samples will have fully informed consent for use in research.
Key exclusion criteria (2 listed)
- Samples taken without consent for use in future research
- Samples taken from individuals without the capacity to consent to use in research
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sample collectionNew collected samples, as well as surplus surgical and diagnostic samples. | Other | – |
Primary outcome
This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches.
Time frame: 10 years
Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jul 2024.
Related trials for Human Development
RecruitingObservational study
Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research
Endothelial Dysfunction, Inflammation in Cardiopulmonary and Vascular Disease States
Not yet recruiting
Milk Free From A1-Type β-Casein With Human Milk Oligosaccharides on Gut Health, Immunity, Cognitive Development, and Temperament in Toddlers
Healthy Volunteers
RecruitingObservational study
A Study on Associations Between Multidimensional Human Phenotypic Traits and Human Growth and Development
Musculoskeletal Growth and Development
RecruitingPhase 1/2
Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism
Autism Spectrum Disorder (ASD, Prospective Study
Active, not recruitingPhase 1
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sarah Teichmann principal investigator
Wellcome Sanger Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Development and Genetic Disease, run by The Wellcome Sanger Institute at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 12 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches. (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2024.